Heart fatty acid binding protein as a marker for postmortem detection of early myocardial damage

Meng, Xiangchao; Ming, Mei; Wang, Enyin

doi:10.1016/j.forsciint.2005.08.008

Cited by 58 publications

(46 citation statements)

References 13 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In both the groups, H-FABP had the highest area under curve followed by myoglobin and CK-MB [ biomarker used for the diagnosis of AMI in hyperacute phase (within 3 hours after the onset of symptoms). However, myoglobin is not a specific marker as its concentration is much higher in skeletal muscles than cardiac tissue [19].…”

Section: Resultsmentioning

confidence: 99%

Heart-Type Fatty Acid Binding Protein: A Better Cardiac Biomarker than CK-MB and Myoglobin in the Early Diagnosis of Acute Myocardial Infarction

Pyati¹

2015

JCDR

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Heart-Type Fatty Acid Binding Protein: A Better Cardiac Biomarker than CK-MB and Myoglobin in the Early Diagnosis of Acute Myocardial Infarction

Pyati¹

2015

JCDR

View full text Add to dashboard Cite

“…Indeed, clinical studies have shown that increased levels of human FABP (or FABP3) can be detected earlier and with higher sensitivity in patients with acute myocardial infarction compared with cTnI (Cubranic et al, 2012;McMahon et al, 2012). This assumption is supported by studies on human autopsy cases showing that FABP leakage already occurs early after myocardial infarction in the absence of myocyte necrosis (Meng et al, 2006). Secondly, FABP3 might be a sensitive marker for various cardiovascular risks, beyond acute myocardial injury.…”

Section: Figurementioning

confidence: 96%

Chronic drug‐induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell‐derived cardiomyocytes

Kopljar

Bondt

Vinken

et al. 2017

British J Pharmacology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSEIn the pharmaceutical industry risk assessments of chronic cardiac safety liabilities are mostly performed during late stages of preclinical drug development using in vivo animal models. Here, we explored the potential of human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) to detect chronic cardiac risks such as drug-induced cardiomyocyte toxicity. EXPERIMENTAL APPROACHVideo microscopy-based motion field imaging was applied to evaluate the chronic effect (over 72 h) of cardiotoxic drugs on the contractile motion of hiPS-CMs. In parallel, the release of cardiac troponin I (cTnI), heart fatty acid binding protein (FABP3) and N-terminal pro-brain natriuretic peptide (NT-proBNP) was analysed from cell medium, and transcriptional profiling of hiPS-CMs was done at the end of the experiment. KEY RESULTSDifferent cardiotoxic drugs altered the contractile motion properties of hiPS-CMs together with increasing the release of cardiac biomarkers. FABP3 and cTnI were shown to be potential surrogates to predict cardiotoxicity in hiPS-CMs, whereas NT-proBNP seemed to be a less valuable biomarker. Furthermore, drug-induced cardiotoxicity produced by chronic exposure of hiPS-CMs to arsenic trioxide, doxorubicin or panobinostat was associated with different profiles of changes in contractile parameters, biomarker release and transcriptional expression. CONCLUSION AND IMPLICATIONSWe have shown that a parallel assessment of motion field imaging-derived contractile properties, release of biomarkers and transcriptional changes can detect diverse mechanisms of chronic drug-induced cardiac liabilities in hiPS-CMs. Hence, hiPS-CMs could potentially improve and accelerate cardiovascular de-risking of compounds at earlier stages of drug discovery.

show abstract

“…Basic and clinical research using rats and human autopsy cases has found that leakage of H-FABP occurs despite the absence of myocyte necrosis (26). H-FABP is a low molecular weight protein that is confined to the cytoplasm and is released into the circulation through the porous membranes of damaged myocardial cells (22).…”

Section: Clinical Outcomes and Myocardial Damage In Chf-af Patientsmentioning

confidence: 99%

Prognostic Value of Myocardial Damage Markers in Patients with Chronic Heart Failure with Atrial Fibrillation

et al. 2014

View full text Add to dashboard Cite

Objective The aim of the present study was to examine the relationship between myocardial damage caused by atrial fibrillation (AF) and subsequent cardiovascular events in AF patients with chronic heart failure (CHF). Methods and ResultsWe measured the serum levels of heart-type fatty acid binding protein (H-FABP) and high-sensitivity troponin T in 402 consecutive CHF patients with chronic AF (CHF-AF, n=201) or sinus rhythm (CHF-SR, n=201). The patients with CHF-AF had higher H-FABP and troponin T levels than those with CHF-SR. In order to examine the prognostic value of myocardial damage markers in CHF-AF and CHF-SR patients, we followed the above patients and analyzed their clinical outcomes. A multivariate Cox proportional hazard analysis revealed that both the serum H-FABP and troponin T levels independently predicted subsequent cardiovascular events. A Kaplan-Meier analysis demonstrated that the rate of cardiovascular events was higher in the patients with elevated H-FABP and troponin T levels. The optimal cut-off values for the myocardial damage markers of cardiovascular events were higher in the CHF-AF patients than in the CHF-SR patients (H-FABP, 5.4 vs. 4.6 ng/mL and troponin T, 0.030 vs. 0.013 ng/mL). Conclusion Myocardial damage advances in association with the presence of AF and is associated with subsequent cardiovascular events in both CHF-AF and CHF-SR patients. In this study, the cut-off values for the myocardial damage markers were higher in the CHF-AF patients than in the CHF-SR patients.

show abstract

Heart fatty acid binding protein as a marker for postmortem detection of early myocardial damage

Cited by 58 publications

References 13 publications

Heart-Type Fatty Acid Binding Protein: A Better Cardiac Biomarker than CK-MB and Myoglobin in the Early Diagnosis of Acute Myocardial Infarction

Heart-Type Fatty Acid Binding Protein: A Better Cardiac Biomarker than CK-MB and Myoglobin in the Early Diagnosis of Acute Myocardial Infarction

Chronic drug‐induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell‐derived cardiomyocytes

Prognostic Value of Myocardial Damage Markers in Patients with Chronic Heart Failure with Atrial Fibrillation

Contact Info

Product

Resources

About